‘We are in a cottage industry that is consolidating due to regulation,’ enthused Alex Alway, chief executive of acquisitive corporate and financial consultancy Jelf, one of Growth Company Investor’s best-performing recommendations from last year.
Wales and Southern England-focused Jelf, backed at 135p, delivered a 148% pre-tax profits surge to £3.3m for a year to September in which six acquisitions were completed, on turnover more than doubled to £25.1m. Acquisitions delivered £9.1m of the £13.6m sales rise, although growth also reflected new client wins and healthy levels of cross-selling. Despite all this investment, Jelf delivered a tidy 17% operating margin climb to 13.1%.
Alway announced 175% revenue growth within the insurance business, which provides commercial insurance broking services to corporate clients and now represents 42% of sales, with acquisitions including Goss (the company’s biggest acquisition last year) enhancing the performance.
Healthcare, entailing the provision of advice on matters such as private medical insurance, posted 20% sales growth thanks to new corporate client mandates, while the employee benefits division, ‘a real hot spot for us with employers looking to get more bang for their buck’, enjoyed a 190% revenue rise. In addition, Alway flagged up excellent 99% growth within the wealth management arm, with business boosted by the A-Day pensions legislation and the introduction of Jelf’s own branded SIPP.
Alongside the results, Alway announced the £10m acquisition of specialist healthcare intermediary SPS WellBeing, ‘a business with 2,000-plus corporate accounts’ into which Jelf can cross-sell services.
For 2007, analysts are looking for profits of £5.9m and 16.8p of earnings, placing Jelf on a forward p/e of less than 15 – inexpensive given that earnings should grow by at least 35% this year. Readers who followed our advice are already sitting on super gains, and might consider topping up holdings. Add.
Market cap: £60.8m
PE Forecast: 15
Share price: 248p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.